Free Trial

Editas Medicine (EDIT) Stock Forecast & Price Target

$5.54
+0.07 (+1.28%)
(As of 07/12/2024 ET)

Editas Medicine - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$12.90
132.85% Upside
High Forecast$20.00
Average Forecast$12.90
Low Forecast$7.00
TypeCurrent Forecast
7/15/23 to 7/14/24
1 Month Ago
6/15/23 to 6/14/24
3 Months Ago
4/16/23 to 4/15/24
1 Year Ago
7/15/22 to 7/15/23
Consensus Rating
Hold
Hold
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
4 Hold rating(s)
7 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$12.90$12.90$15.00$15.93
Forecasted Upside132.85% Upside76.65% Upside60.58% Upside53.47% Upside
Get Editas Medicine Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

EDIT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EDIT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Editas Medicine Stock vs. The Competition

TypeEditas MedicineMedical CompaniesS&P 500
Consensus Rating Score
2.40
2.71
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside132.85% Upside994.16% Upside9.19% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/18/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform ➝ Market Perform$12.00 ➝ $12.00+138.57%
5/30/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Bayko
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetIn-Line ➝ In-Line$15.00 ➝ $7.00+36.99%
5/9/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$16.00 ➝ $15.00+174.22%
5/9/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$11.00 ➝ $9.00+64.84%
5/9/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight$7.00+39.03%
2/27/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$8.00 ➝ $9.00+3.09%
12/12/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$15.00 ➝ $20.00+102.43%
10/17/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral
9/28/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$9.00 ➝ $17.00+145.66%
8/2/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$22.00 ➝ $19.00+107.88%
6/12/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$17.00+80.47%
2/23/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$13.00 ➝ $15.00+52.91%
2/23/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Perform$14.00 ➝ $10.00+2.56%
2/23/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$36.00 ➝ $30.00+207.69%
1/23/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Bienkowski
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetMarket Perform$6.00 ➝ $7.00-14.43%
11/18/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$18.00 ➝ $15.00+43.13%
11/18/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$25.00 ➝ $18.00+63.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:52 PM ET.

EDIT Forecast - Frequently Asked Questions

What is Editas Medicine's forecast for 2024?

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Editas Medicine is $12.90, with a high forecast of $20.00 and a low forecast of $7.00.

Should I buy or sell Editas Medicine stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.

Does Editas Medicine's stock price have much upside?

According to analysts, Editas Medicine's stock has a predicted upside of 87.77% based on their 12-month stock forecasts.

Has Editas Medicine been upgraded by Wall Street analysts recently?

Over the previous 90 days, Editas Medicine's stock had 1 upgrade by analysts.

What analysts cover Editas Medicine?

Editas Medicine has been rated by research analysts at Barclays, Citigroup, Evercore ISI, Morgan Stanley, and Oppenheimer in the past 90 days.

Do Wall Street analysts like Editas Medicine more than its competitors?

Analysts like Editas Medicine less than other "medical" companies. The consensus rating for Editas Medicine is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EDIT compares to other companies.


This page (NASDAQ:EDIT) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners